Fig. 3.

Notch3 associates with β-catenin in an EGFR TKI-dependent manner. a HCC4006 and b HCC827 cells were treated with DMSO or 0.1 μM erlotinib for 1 or 6 days and cell lysates were immunoprecipitated (IP) with an antibody recognizing Notch3 and blotted (WB) with antibodies recognizing β-catenin or Notch3. A reciprocal IP with an anti-β-catenin antibody was performed and blotted with anti-Notch3 and anti-β-catenin antibodies. c HCC827 cells were treated with erlotinib or GSI alone or in combination and cell lysates were immunoprecipitated with Notch3 and blotted with β-catenin antibody. Cell lysates were also analyzed for Notch3, β-catenin, and β-tubulin. d HCC4006 and e HCC827 cells were treated for 6 days with vehicle (DMSO) or 0.1 μM erlotinib and stained with DAPI and probed with anti-Notch3 and anti-β-catenin antibodies. Images were overlayed to show co-localization. For (d) and (e) scale bar is 30 μm. Error bars represent SD from technical triplicates